Cagrilintide

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia[1-2].

The most frequent adverse events were gastrointestinal disorders (e.g., nausea, constipation, and diarrhoea) and administration-site reactions. More participants receiving cagrilintide 0·3-4·5 mg had gastrointestinal adverse events compared with placebo (41%-63% vs 32%), primarily nausea (20%-47% vs 18%)[5].